Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.
BACKGROUND Studies in Western population s have shown the benefits of pretreatment with atorvastatin in preventing cardiovascular events in patients , including those with acute coronary syndromes ( ACS ) , undergoing percutaneous coronary intervention ( PCI ) . However , data concerning the value of such therapy in Asian patients are limited . The primary objective of the present study is to evaluate the efficacy of atorvastatin in reducing cardiovascular outcomes in Asian patients with non-ST-segment elevation (NSTE)-ACS following hospital admission for early PCI ( within 72 h of the onset of symptoms ) . Secondary objectives are to assess the effects of atorvastatin on cardiac biomarker levels , and the safety and tolerability profile of atorvastatin . METHODS This study is a prospect i ve , multicenter , open-label trial design ed to enroll 350 statin-naïve patients with NSTE-ACS scheduled for PCI in China and the Republic of Korea . Patients are r and omized to either usual care or atorvastatin treatment groups , with patients in both treatment groups receiving usual care including atorvastatin 40 mg/day for 30 days post-PCI . Patients in the atorvastatin group receive additional doses of atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI . The primary end point is the incidence of major adverse cardiac events ( death , myocardial infa rct ion , and target vessel revascularization ) at 30 days post-PCI . CONCLUSIONS The present study will provide valuable insights into whether the benefits of atorvastatin pretreatment extend to Asian patients with ACS undergoing interventions . Enhanced treatment of these patients will be an important contribution towards alleviating the increasing burden of cardiovascular disease in Asian countries
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .